Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuro-Hitech has entered into an agreement with Numoda, pursuant to which Numoda will review the results of the company's recently completed Phase II clinical trial of Huperzine A in mild to moderate Alzheimer's disease patients.
Subscribe to our email newsletter
After completing its review and delivering a report of its findings to Neuro-Hitech, Numoda will also assist the company in interpreting and presenting the results to potential licensing partners, purchasers or acquisition or merger candidates.
Gary Shearman, CEO of Neuro-Hitech, said: “Based upon a detailed review of Phase II results of Huperzine A, we feel confident that there is substantial support within the results that Huperzine A can become a safe and effective treatment for Alzheimer’s disease. We continue to plan for future clinical trials and develop our regulatory approval and commercial strategy.”